Figene, LLC
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Thereof (US 11,732,239) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells (US 11,819,555) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis (US 11,878,037) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Augmentation of Fibroblast Regenerative Activity (US 11,959,102) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof (US 11,975,030) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,819,555 | Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells In force · High confidence | In force | High confidence | |
| US 11,959,102 | Augmentation of Fibroblast Regenerative Activity In force · High confidence | In force | High confidence | |
| US 11,975,030 | Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,732,239 | Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Thereof In force · High confidence | In force | High confidence | |
| US 11,878,037 | Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 5: 6 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
12 pending · 14 abandoned · 28 no status recorded